MBHB Snippets: Review of Developments in Intellectual Property Law - Volume 10, Issue 1 - Winter 2012

In This Issue:

1 - Deciphering the Patent-Eligibility Message in Prometheus, Myriad and Classen

1 - Accelerated Examination v. Prioritized Examination

11 - Now What? Strategies for Responding to Final Office Actions

Excerpt from "Deciphering the Patent-Eligibility Message..."

It has been a little more than eighteen months after the Supreme Court issued its opinion on the patent-eligibility of (business) method claims in Bilski v. Kappos. In that time, the Federal Circuit has issued opinions in Prometheus Laboratories, Inc. v. Mayo Collaborative Services, Classen Immunotherapies, Inc. v. Biogen Idec, and Association for Molecular Pathology v. U.S. Patent and Trademark Office (“Myriad”) relating to diagnostic method claims. These decisions came in the wake of the Supreme Court’s Bilski decision, and two of them (Prometheus and Classen) were decided on remand from the Court for reconsideration in view of Bilski. The Federal Circuit decided the Prometheus case on remand, finding (again) that the claims recited patent-eligible subject matter. The Supreme Court has again granted certiorari for Prometheus; oral arguments were heard late last year and a decision is due by the end of the Court’s current term in June. Of the other two diagnostic method claims cases, the Federal Circuit decided that some but not others of the Classen claims were patent-eligible, and that none of the method claims at issue in Myriad satisfied the Supreme Court test for patent eligibility. Petitions for certiorari have been filed in both the Classen and Myriad cases.

Please see full issue below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

Published In:

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »


At McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB"), we provide creative, pragmatic business... View Profile »

Follow McDonnell Boehnen Hulbert & Berghoff LLP:

Reporters on Deadline

All the intelligence you need, in one easy email:

Great! Your first step to building an email digest of JD Supra authors and topics. Log in with LinkedIn so we can start sending your digest...

Sign up for your custom alerts now, using LinkedIn ›

* With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name.